MAPT and Alzheimer disease: Genetic and animal modeling data from the study of FTDP-17 MAPT only directly support tau as a therapeutic target in FTDP-17 MAPT; however, given the prominence of tau pathology in the AD brain, its correlation with clinical symptoms, and experimental evidence that Aβ can drive tau pathology in vivo, tau remains an attractive theoretical target in AD [104].